Do Weight-Loss drugs save money? new study investigates

NCT ID NCT07640139

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 16, 2026

Summary

This observational study will follow 125,000 adults with employer-based insurance to see how GLP-1 and GLP-1/GIP obesity medications (like Wegovy and Zepbound) affect weight, healthcare use, and medical costs. Researchers will compare people who take these drugs to those who don't, using existing medical and pharmacy claims data. The goal is to understand the real-world impact of these popular medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Indiana University

    Indianapolis, Indiana, 46203, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Incretin-based therapies (GLP-1 and GLP-1/GIP drugs like Wegovy, Zepbound)

What this could lead to

If successful, this study could provide real-world evidence on whether these medications improve health and reduce healthcare costs for people with obesity.

What could go wrong

This is an observational study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to people outside employer-based insurance.

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.